FOXG1 and myeloid sarcoma: Our findings revealed a previously-unknown function of Foxg1 in oligodendrocyte lineage cells, suggesting that downregulating the expression of Foxg1 in the treatment of demyelinating CNS diseases may alleviate demyelination and promote remyelination, thus providing a new gene therapy target for demyelinating CNS diseases such as MS.